Annual Reports in Medicinal Chemistry, Volume 37

I. CENTRAL NERVOUS SYSTEM DISEASES

Section Editor: David W. Robertson, Pfizer Global Research & Development, Ann Arbor, MI

1. Promise and Progress of Central G-Protein Coupled Receptor Modulators 1 for Obesity Treatments Brian L. Largent, Albert J. Robichaud and Keith J. Miller, Bristol-Myers Squibb Company, Wilmington, Delaware

2. Attention Deficit Hyperactivity Disorder: Pathophysiology and Design of 11 New Treatments Shelly A. Glase, Larry D. Wise and David W. Robertson, Pfizer Global Research and Development, Ann Arbor, Michigan

3. 5-HT2C Receptor Modulators: Progress in Development of 21 New CNS Medicines
   Larry E. Fitzgerald and Michael D. Ennis, Pharmacia Corporation, Kalamazoo, Michigan

4. Emerging Themes in Alzheimer's Disease Research: Paradigm Shift in Drug Discovery 31 Todd Morgan, School of Gerontology, University of Southern California, Los Angeles, California and Grant A. Krafft, Acumen Pharmaceuticals, Glenview, Illinois

II. CARDIOVASCULAR AND PULMONARY DISEASES

Section Editor: William J. Greenlee, Schering-Plough Research Institute, Kenilworth, New Jersey

5. Recent Advances in Pulmonary Hypertension Therapy 41
   Russell A. Bialecki, AstraZeneca Pharmaceuticals, Wilmington, Delaware

6. Phosphodiesterase 5 Inhibitors 53
   Andrew W. Stamford, Schering-Plough Research Institute, Kenilworth, New Jersey

7. Antagonists of VLA-4 65
   George W. Holland, Ronald J. Biediger, and Peter Vanderslice, Texas Biotechnology Corporation, Houston, Texas

8. Purine and Pyrimidine Nucleotide (P2) Receptors 75 Kenneth A. Jacobson, Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland

9. Anticoagulants: Inhibitors of the Factor VIIa/ Tissue Factor Pathway 85
   Leslie A. Robinson and Eddine M. K. Saiah, Deltagen Research Laboratories, San Diego, California

III. CANCER AND INFECTIOUS DISEASES

Section Editor: Jacob J. Plattner, Chiron Corporation, Emeryville, California

10. The Prospect for Microbial Genomics Providing Novel, Exploitable, 95 Antibacterial Targets
    Thomas J. Dougherty, Pfizer Global Research & Development, Groton, Connecticut and John F. Barrett, Merck Research Laboratories, Rahway, New Jersey

11. The Chemistry and Biology of Tetracyclines 105
    Mark L. Nelson, Paratek Pharmaceuticals, Inc., Boston, Massachusetts

12. Intracellular Signaling Targets for Cancer Chemosensitization 115
    Thomas G. Gesner and Stephen D. Harrison, Chiron Corporation, Emeryville, California

13. Emerging Microtubule Stabilizing Agents for Cancer Chemotherapy 125
    David C. Myles, Kosan Biosciences, Inc., Hayward, California

14. Antiviral Agents 133 Nicholas A. Meanwell, John F. Kadow and Paul M. Scola, The Bristol-Myers Squibb Pharmaceutical Research Institute Wallingford, Connecticut

15. Aerosol Delivery of Antibiotics 149
    Peter B. Challoner, Chiron Corporation, Emeryville, California

IV. IMMUNOLOGY, ENDOCRINOLOGY AND METABOLIC DISEASES

Section Editor: William K. Hagmann, Merck Research Laboratories, Rahway, New Jersey

16. Therapeutic Applications of Non-peptidic d-Opioid Agonists 159
    Graham N. Maw and Donald S. Middleton, Pfizer Global Research and Development, Department of Discovery Chemistry, Sandwich, Kent

17. Selective Glucocorticoid Receptor Modulators 167
    Michael J. Coghlan, Steven W. Elmore†, Philip R. Kym† and Michael E. Kort†, Eli Lilly and Company, Discovery Chemistry Research & Technologies, DC , †Lilly Corporate Center, Indianapolis, Indiana, Abbott Laboratories, Global Pharmaceutical Research and Development, Illinois

18. Inhibitors of p38 a MAP Kinase 177
    Sarvajit Chakravarty and Sundeep Dugar, Scios Inc. Sunnyvale, California

V. TOPICS IN BIOLOGY

Section Editor: Janet M. Allen, Inpharmatica, London, United Kingdom

19. Expanding and Exploring Cellular Pathways for Novel Drug Targets 187 Malcolm P. Weir, John P. Overington and Marlon Schwarz, Inpharmatica Ltd., London,

20. Searching for Alzheimer's Disease Therapies In Your Medicine Cabinet: 197 The Epidemiological and Mechanistic Case For NSAIDs and Statins Robert B. Nelson, Pfizer Global Research and Development, Groton, Connecticut

21. Matrix Metalloproteinases and the Potential Therapeutic Role for Matrix 209
    Metalloproteinase Inhibitors in Chronic Obstructive Pulmonary Disease Kevin M. Bottomley and Maria G. Belvisi, Inpharmatica, London and Respiratory Pharmacology, Cardiothoracic Surgery, Imperial College School of Medicine, National Heart and Lung Institute, London

22. Fc Receptor Structure and the Design of Anti-inflammatories: New 217 Therapeutics For Autoimmune Disease. Geoffrey A. Pietersz, Maree S. Powell, Paul A. Ramsland and P. Mark Hogarth, Austin Research Institute, Austin and Repatriation Medical Center, Victoria, Australia

23. Tumor classification for tailored cancer therapy 225 Fiona McLaughlin and Nick LaThangue, Prolifix Ltd, Abingdon, Oxon

VI. TOPICS IN DRUG DESIGN AND DISCOVERY

Section Editor: George L. Trainor, DuPont Pharmaceuticals Company, Wilmington, Delaware

24. Advances in the Discovery and Characterization of Ion Channel 237
    Modulators: Focus on Potassium Channels
    Valentin K. Gribkoff and John E. Starrett, Jr., Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut
25. Microwave-Assisted Chemistry as a Tool for Drug Discovery 247
    Carolyn D. Dzierba and Andrew P. Combs, Bristol-Myers Squibb Co. Experimental Station, Wilmington, Delaware

VII. TRENDS AND PERSPECTIVES

Section Editor: Annette M. Doherty, Pfizer Global Research & Development, Fresnes Laboratories, Fresnes, France

26. To Market, To Market - 2001 257
    Patrick Bernardelli, Bernard Gaudillière and Fabrice Vergne, Pfizer Global Research & Development, Fresnes Laboratories, Fresnes, France

27. Biosimulation: Dynamic Modeling of Biological Systems 279
    Kevin Hall, Rebecca Baillie, and Seth Michelson, Entelos Inc., Menlo Park, California

COMPOUND NAME, CODE NUMBER AND SUBJECT INDEX, VOLUME 37 289

CUMULATIVE CHAPTER TITLES KEYWORD INDEX, VOLUMES 1-37 297

CUMULATIVE NCE INTRODUCTION INDEX, 1983-2001 315

CUMULATIVE NCE INTRODUCTION INDEX, 1983-2001, BY INDICATION 331

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.

Medicinal, pharmaceutical, and organic chemists.